NASDAQ
MDXH
Last Price
US $0.42
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
MDxHealth S.A. cash flow to debt ratio of -10.95% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
MDxHealth S.A.'s free cash flow has increased -44.06% from $-20.69M last year to $-11.57M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
MDxHealth S.A.'s debt to equity ratio is -7.86, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
MDxHealth S.A.'s debt to equity ratio is -7.86, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Net debt/EBITDA.
MDxHealth S.A. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
MDxHealth S.A.'s interest coverage ratio is -0.92, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
MDxHealth S.A.'s profit margin has increased (-23.90%) in the last year from -42.28% to -32.17%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
MDxHealth S.A.'s short-term assets of $53.41M exceed its short-term liabilities of $49.53M
Decreasing performance - ROA.
MDxHealth S.A.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
MDxHealth S.A.'s return on equity of 402.97%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
MDxHealth S.A.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
MDxHealth S.A. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
MDxHealth S.A. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
MDxHealth S.A. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
MDxHealth S.A.'s yearly earnings has increased -11.95% since last year from $-38.07M to $-33.52M, signaling increasing performance
Increasing performance - Healthy revenue growth.
MDxHealth S.A.'s yearly revenue has increased 19.80% since last year from $90.05M to $107.88M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -12.74% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
MDxHealth S.A.'s 3-year revenue CAGR of 42.79% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
MDxHealth S.A. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
MDxHealth S.A. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
MDxHealth S.A. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
MDxHealth S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
MDxHealth S.A. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
MDxHealth S.A. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
MDxHealth S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
MDxHealth S.A. has negative shareholder equity; price-to-book is not meaningful and the check fails
Undervalued - P/S ratio.
MDxHealth S.A. has a price-to-sales ratio of 0.26x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
402.97%
Return on equity
ROIC: -12.74%
Valuation History
-0.71X
Price to Earnings
EV/EBITDA: -15.2X
Cash flow
Profit margin
11.35%
(FY vs FY)
Cash flow Y/Y
12.42%
(FY vs FY)
Fair Value
Market $0.42
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.